Sei Investments Co. Has $47.12 Million Position in Kenvue Inc. (NYSE:KVUE)

Sei Investments Co. increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,207,060 shares of the company’s stock after buying an additional 20,802 shares during the quarter. Sei Investments Co.’s holdings in Kenvue were worth $47,121,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Mizuho Securities USA LLC raised its position in shares of Kenvue by 46.3% in the fourth quarter. Mizuho Securities USA LLC now owns 181,712 shares of the company’s stock valued at $3,880,000 after purchasing an additional 57,524 shares during the period. Virtu Financial LLC acquired a new position in shares of Kenvue in the fourth quarter worth approximately $1,269,000. Millstone Evans Group LLC bought a new stake in shares of Kenvue during the 4th quarter valued at about $565,000. TD Private Client Wealth LLC lifted its position in shares of Kenvue by 116.6% during the 4th quarter. TD Private Client Wealth LLC now owns 279,728 shares of the company’s stock valued at $5,972,000 after acquiring an additional 150,601 shares during the period. Finally, Berkeley Capital Partners LLC increased its position in Kenvue by 1.2% in the 4th quarter. Berkeley Capital Partners LLC now owns 69,250 shares of the company’s stock valued at $1,478,000 after buying an additional 816 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KVUE has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Canaccord Genuity Group raised their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Finally, Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $23.75.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.34 on Monday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market capitalization of $44.61 billion, a PE ratio of 44.04, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock’s fifty day moving average is $22.08 and its two-hundred day moving average is $22.43. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.